
AI-generated summary
The Mideast conflict has persisted, raising concerns about regional stability and energy security. The Strait of Hormuz, a vital chokepoint for global oil transit, has been a focal point of tensions. Diplomatic channels between the U.S. and Iran have been reactivated through third-party mediation.
Oil rose Tuesday, extending gains for a second day, as worries over the Mideast conflict continuing for longer take hold, even as efforts to reduce tensions are reportedly underway.
Futures for international benchmark Brent crude for November delivery gained 1.22% to $106.56 a barrel. U.S. West Texas Intermediate futures advanced over 1% to $93.57 per barrel.
The U.S. and Iran are talking separately to mediators as part of renewed efforts to end the conflict. Citing Iranian Foreign Minister Abbas Araghchi, Al Jazeera reported that Tehran held indirect talks with the U.S. via Qatari mediators in New York.
Progress in talks will be a main focus, as regional mediators push for ceasefire negotiations, said Mahmoud Mashal, senior market analyst of VT Markets Dubai, adding that any meaningful progress could drive crude lower.
That said, concerns over energy infrastructure and flows in the region continue to linger due to renewed tensions between Saudi Arabia and the Houthis, Mashal said.
The Strait of Hormuz, a crucial waterway that saw 20% of the world's oil supply transit through it prior to the war, remains closely watched.
Trump on Saturday had rejected Tehran's conditional proposal for reopening the strait, telling aides that he expects to resume bombing Iran following the midterm elections in November.
AI outlook — possibilities, not facts
If diplomatic talks between the U.S. and Iran yield concrete progress on de-escalation, oil prices could decline significantly in the coming weeks.
Possible · Within weeks
Continued tensions between Saudi Arabia and the Houthis will likely maintain upward pressure on oil prices through potential threats to shipping in the Red Sea and surrounding waters.
Likely · Within weeks

Luckin Coffee is evaluating expansion into Gulf countries with support from Abu Dhabi's Mubadala sovereign wealth fund, which invested $1 billion alongside Centurium Capital in September. Chairman David Li confirmed the Gulf market assessment in a CNBC interview, noting the company's turnaround under Centurium's backing and its position as China's largest coffee chain by sales, surpassing Starbucks. Luckin previously attempted Middle East expansion in 2019 but failed to execute, and its shares now trade over-the-counter at a $9.6 billion valuation following a 2019 accounting scandal that led to U.S. bankruptcy and Nasdaq delisting.

Samsung Electronics and its affiliates will invest a combined $1 billion in Helix Digital Infrastructure, an AI infrastructure company backed by KKR and Nvidia, to support global AI data center rollout and power infrastructure needs.

U.S. Treasury yields increased on Monday due to rising oil prices and inflation fears, with the 10-year note up over 5 basis points to 5.234%, the 30-year bond up nearly 6 basis points to 5.56%, and the 2-year note up more than 5 basis points to 4.918%. Global bond yields also rose as investors await key U.S. economic data releases later in the week.

President Donald Trump will announce a $15 billion investment by Mesabi Metallics to build the largest steel plant in U.S. history in Iowa, with production slated to begin in 2030. The project, tied to the company's Minnesota iron ore mine, aims to create thousands of jobs and comes weeks before the midterm elections amid criticism of Trump's economic handling and steel tariffs.

Diesel prices are increasing globally due to refinery disruptions from Ukrainian attacks on Russian facilities and Hormuz tensions, with the US considering export bans ahead of midterm elections, while Europe faces disproportionate impact due to its diesel-dependent vehicle fleet and transport sector, leading to billions in added economic costs.

BioNTech will close three sites in Germany after failing to find buyers, affecting around 1,800 employees, as part of a restructuring driven by falling COVID-19 vaccine demand and a shift toward oncology, with expected annual savings of €500 million.